Global InformationStallergenes Greer information
 | This article contains content that is written like an advertisement. (November 2022) |
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 2015 |
| Headquarters | Baar, Switzerland |
Key people | Stefan Meister (Chairman), Michele Antonelli (Chief Executive Officer), Giampiero De Luca (Board member) |
| Revenue |  € 277 million (2018) [1] |
Net income | 12,8 M€ (2018) |
Number of employees | 1045 (2021) |
Stallergenes Greer International AG is a global biopharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.[2]
Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc.[3] (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France).[4]
With 1035 employees in 2021,[5] Stallergenes Greer operates in 19 countries.[6]
Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France) and in the USA (Lenoir, North Carolina and San Diego, California).[7]
- ^ "Annual report" (PDF). stallergenesgreer.com. 2018.
- ^ "STALLERGENES GREER LTD". Companies House.
- ^ "STALLERGENES GREER LTD". Companies House.
- ^ "STALLERGENES SAS". infogreffe.fr.
- ^ "Key facts and figures". stallergenesgreer.com.
- ^ "Global Network | stallergenesgreer.com". www.stallergenesgreer.com. Retrieved 2020-05-21.
- ^ "Annual Report 2018" (PDF). 2018.